Element Biosciences, the developer of the AVITI benchtop sequencer, will be sharing details about its technology and discussing customer stories at the annual meeting of the American Society of Human ...
SAN DIEGO, Aug. 13, 2024 /PRNewswire/ -- Avidity Biosciences, Inc. (Nasdaq: RNA), a biopharmaceutical company committed to delivering a new class of RNA therapeutics called Antibody Oligonucleotide ...
Delpacibart etedesiran data from MARINA-OLE™ showed reversal of disease progression in multiple functional measures in DM1 compared to END-DM1 natural history data "We are pleased that the FDA has ...
While next generation sequencing (NGS) has become a staple method for some researchers, it is often out of reach due to its high cost and technical challenges. To solve this problem, a novel ...
Ongoing verification study supports compatibility of DeepChek® with the AVITI™ platform. Expands opportunities in infectious disease sequencing workflows. WOIPPY ...
In a deal that could bring Avidity Biosciences Inc. $2.3 billion if all milestones are met, Bristol Myers Squibb Co. gained global licensing and research rights to Avidity’s antibody oligonucleotide ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results